-+ 0.00%
-+ 0.00%
-+ 0.00%

ExpreS2ion Q3 loss after financial items widens 28% to SEK 12.46 million

PUBT·11/12/2026 07:34:42
Listen to the news
ExpreS2ion Q3 loss after financial items widens 28% to SEK 12.46 million
  • ExpreS2ion’s third-quarter 2026 loss widened 18% year over year to SEK 9.94 million.
  • Nine-month operating income more than doubled year over year to SEK 20.71 million.
  • Cash at September-end fell 35% year over year to SEK 23.96 million.
  • ES2B-C001 Phase I enrollment reached completion with 19 patients dosed; 12 of 13 evaluable patients showed anti-HER2 antibody responses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.